Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
Author:
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Link
http://link.springer.com/article/10.1007/s40273-018-0653-2/fulltext.html
Reference43 articles.
1. de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.
2. Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52(2):141–50.
3. Erim DO, Mahendraratnam N, Okafor PN, Wheeler SB. The value of vedolizumab as rescue therapy in moderate-severe Crohn’s disease patients with adalimumab non-response in the USA. J Crohns Colitis. 2015;9(8):669–75.
4. Rencz F, Gulácsi L, Péntek M, et al. Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe. Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):597–606.
5. Baji P, Gulácsi L, Péntek M, et al. Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe. United Eur Gastroenterol J. 2018;6(2):310–21.
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies;Expert Opinion on Biological Therapy;2024-02-23
2. The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate–Severe Crohn’s Disease: A Systematic Review;Pharmaceuticals;2023-11-08
3. Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease;Cureus;2023-10-11
4. Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy;AboutOpen;2023-01-16
5. Real-world effectiveness of ustekinumab in maintenance therapy for Crohn´s disease;Dokazatel'naya gastroenterologiya;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3